Experimental CAR-T therapy targets stubborn autoimmune disease

NCT ID NCT07148791

Recruiting now Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a personalized cell therapy called anti-BCMA-CD19 CAR-T cells in 9 adults with IgG4-related disease that hasn't responded to standard treatments. Participants receive an infusion of their own modified immune cells after a short course of chemotherapy. The study aims to see if the therapy is safe and can reduce disease activity over 26 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-BCMA-CD19 CAR-T cells (a personalized immune cell therapy made from the patient's own blood cells, modified to target specific proteins)
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat IgG4-related disease, potentially reducing symptoms and disease activity without long-term medication.
What could go wrong: This is a very early, small trial with only 9 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and nerve problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL MEDIATED AUTOIMMUNE DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease Immunoglobulin G4-Related Disease immunoglobulin G4-related sclerosing disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL MEDIATED AUTOIMMUNE DISORDERS IGG4-RELATED DISEASE

Contacts and locations

Locations

Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.